

Life Settlement Assets PLC – Ordinary Share E

Investment Objective

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

Commentary

The Associated Press analysed life expectancy and demographic data for 65,662 census tracts, geographic areas that encompass roughly 4,000 residents. The AP found that certain demographic qualities — high rates of unemployment, low household income, a concentration of black or Native American residents and low rates of high school education — affected life expectancy in most neighbourhoods. For example, an increase of 10 percentage points in the unemployment rate in a neighbourhood translated to a loss of roughly a year and a half of life expectancy; similarly a neighbourhood where more adults failed to graduate high school had shorter predicted longevity.

The Share Class is reporting a performance of -2.20% for the month of November. The HIV segment registered \$33k on two small policies. Note that we have also been notified of an additional large maturity - the 2nd largest exposure - for November, but after the cut-off date for that month. The Top 10 coverage table will be updated, and the related performance taken into account, in the forthcoming December monthly.

Investment Terms	Estimated NAV (USD)	NAV/Share
1.5% Management Fee	7,166,871.17	4.1349

Number Of Policies	Death Benefits (USD)	Matured Policies YTD*	Maturities YTD (USD)*
236	22 276 417	13	930 410

Trust Investment Manager Acheron Capital Ltd.

Company Secretary Maitland Administration Services Limited







Administrator Compagnie Européenne de Révision

ISIN Ticker GB00BF1Q4D29
LSAE

Auditor Grant Thornton UK LLP

Info life@acheroncapital.com
+44 207 258 5990

*This figure refers to maturities occurred in the portfolio held by Styx Portfolio Trust




(1) Indicates the available face amount to LSA which is a fractional interest of initial face amount.

(2) Distribution by issue dates reflects the time since the life insurance policy was issued.

Source of Data: Acheron Capital Ltd unless otherwise stated.


Historical Maturity



Maturities November 2018

Number of policies matured in November 2018	2
Corresponding number of insured	2
Total death benefit in November 2018(US\$)	33 450
Valuation of Matured policies in Book (US\$)	7 096

Notification of Maturity



Premiums Situation (US\$) ⁽¹⁾

Servicers Premiums Projection as of Beginning 2018	\$ 1.5M
Mortality Adjusted Premiums Projection Beginning 2018	\$ 1.3M
Estimated COI Net of Mortality Beginning 2018	\$ 1.7M

Top 10 Coverage

Insured	Face (million)	Total Face (millions)	Age (ALB)	Expiration Age*
1	2.2/0.3/0.3	2.8	99	101/101/121
2	1.2/0.7/0.2	2.1	98	115/120/120
3	2	2	98	100
4	0.2/0.2/0.2	0.6	76	100/121/100
5	0.6	0.6	87	95
6	0.3/0.2/0.1	0.6	91	100/100/100
7	0.5	0.5	96	100
8	0.5	0.5	69	95
9	0.4/0.03/0.02	0.4	90	95/95/95
10	0.3	0.3	77	100

Cash Situation (US\$) ⁽¹⁾

Cash at hand and similar	\$ 1.8M
Gross Cash in Policies ⁽²⁾ (estimated as of end 2017)	\$ 821k
Loan on Cash in Policies (estimated as of end 2017)	\$ 0k
Net Cash in Policies ⁽²⁾ (estimated as of end 2017)	\$ 740k
Maturities to be received	\$ 0.2M

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Surrender charge included.

* In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James' Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under reference FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.